- Home
- MX vs HURA Comparison
MX vs HURA Comparison
Compare MX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MX | HURA |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | South Korea | United States |
| Employees | N/A | 22 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 160.5M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | MX | HURA |
|---|---|---|
| Price | $3.42 | $2.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.75 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 1.1M | 370.1K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,860,000.00 | N/A |
| Revenue This Year | $8.55 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $0.41 |
| 52 Week High | $9.86 | $3.90 |
Technical Indicators
Market Signals| Indicator | MX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 43.54 |
| Support Level | $2.45 | $2.14 |
| Resistance Level | $4.76 | $2.20 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 27.87 | 12.00 |
Price Performance
Historical ComparisonAbout MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.